Literature DB >> 24012658

Effects of the hallucinogen 2,5-dimethoxy-4-iodophenethylamine (2C-I) and superpotent N-benzyl derivatives on the head twitch response.

Adam L Halberstadt1, Mark A Geyer2.   

Abstract

N-benzyl substitution markedly enhances the affinity of phenethylamine hallucinogens at the 5-HT(2A) receptor. N-benzyl substituted derivatives of 2,5-dimethoxy-4-iodophenethylamine (2C-I), such as N-(2-methoxybenzyl)-2,5-dimethoxy-4-iodophenethylamine (25I-NBOMe) and N-(2,3-methylenedioxybenzyl)-2,5-dimethoxy-4-iodophenethylamine (25I-NBMD), have appeared recently as designer drugs, but have not been characterized behaviorally. The head twitch response (HTR) is induced by 5-HT(2A) receptor activation in rats and mice, and is widely used as a behavioral proxy for hallucinogen effects in humans. Nevertheless, it is not clear whether phenethylamine hallucinogens reliably provoke this behavior. Hence, we investigated whether 2C-I, 25I-NBOMe and 25I-NBMD induce head twitches in C57BL/6J mice. The HTR was assessed using a head-mounted magnet and a magnetometer coil. 2C-I (1-10 mg/kg SC), 25I-NBOMe (0.1-1 mg/kg SC), and 25I-NBMD (1-10 mg/kg SC) induced the HTR. 25I-NBOMe displayed 14-fold higher potency than 2C-I, and the selective 5-HT(2A) antagonist M100,907 completely blocked the HTR induced by all three compounds. These findings show that phenethylamine hallucinogens induce the HTR by activating 5-HT(2A) receptors. Our results demonstrate that 25I-NBOMe is a highly potent derivative of 2C-I, confirming previous in vitro findings that N-benzyl substitution increases 5-HT(2A) affinity. Given the high potency and ease of synthesis of N-benzylphenethylamines, it is likely that the recreational use of these hallucinogens will become more widespread in the future.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  5-HT2A; Head twitch; LSD; Psychedelic

Mesh:

Substances:

Year:  2013        PMID: 24012658      PMCID: PMC3866097          DOI: 10.1016/j.neuropharm.2013.08.025

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  42 in total

1.  Serotonin, but not N-methyltryptamines, activates the serotonin 2A receptor via a ß-arrestin2/Src/Akt signaling complex in vivo.

Authors:  Cullen L Schmid; Laura M Bohn
Journal:  J Neurosci       Date:  2010-10-06       Impact factor: 6.167

2.  Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists.

Authors:  Michael R Braden; Jason C Parrish; John C Naylor; David E Nichols
Journal:  Mol Pharmacol       Date:  2006-09-25       Impact factor: 4.436

3.  High specific activity tritium-labeled N-(2-methoxybenzyl)-2,5-dimethoxy-4-iodophenethylamine (INBMeO): a high-affinity 5-HT2A receptor-selective agonist radioligand.

Authors:  David E Nichols; Stewart P Frescas; Benjamin R Chemel; Kenneth S Rehder; Desong Zhong; Anita H Lewin
Journal:  Bioorg Med Chem       Date:  2008-04-25       Impact factor: 3.641

4.  An in vivo binding assay to determine central alpha(1)-adrenoceptor occupancy using [(3)H]prazosin.

Authors:  S Patel; E Fernandez-Garcia; P H Hutson; S Patel
Journal:  Brain Res Brain Res Protoc       Date:  2001-12

5.  Screening hallucinogenic drugs: systematic study of three behavioral tests.

Authors:  M T Silva; H M Calil
Journal:  Psychopharmacologia       Date:  1975-05-28

6.  Analytical characterization of three hallucinogenic N-(2-methoxy)benzyl derivatives of the 2C-series of phenethylamine drugs.

Authors:  Dariusz Zuba; Karolina Sekuła
Journal:  Drug Test Anal       Date:  2012-08-31       Impact factor: 3.345

Review 7.  Serotonin research: contributions to understanding psychoses.

Authors:  Mark A Geyer; Franz X Vollenweider
Journal:  Trends Pharmacol Sci       Date:  2008-09       Impact factor: 14.819

8.  MDMA-like behavioral effects of N-substituted piperazines in the mouse.

Authors:  H L Yarosh; E B Katz; A Coop; W E Fantegrossi
Journal:  Pharmacol Biochem Behav       Date:  2007-07-06       Impact factor: 3.533

9.  A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis.

Authors:  Michael A Benneyworth; Zixiu Xiang; Randy L Smith; Efrain E Garcia; P Jeffrey Conn; Elaine Sanders-Bush
Journal:  Mol Pharmacol       Date:  2007-05-25       Impact factor: 4.436

10.  Facilitation of 8-OHDPAT-induced forepaw treading of rats by the 5-HT2 agonist DOI.

Authors:  J Arnt; J Hyttel
Journal:  Eur J Pharmacol       Date:  1989-02-14       Impact factor: 4.432

View more
  36 in total

1.  "My friend said it was good LSD": a suicide attempt following analytically confirmed 25I-NBOMe ingestion.

Authors:  Joji Suzuki; Justin L Poklis; Alphonse Poklis
Journal:  J Psychoactive Drugs       Date:  2014 Nov-Dec

Review 2.  Toxicities associated with NBOMe ingestion-a novel class of potent hallucinogens: a review of the literature.

Authors:  Joji Suzuki; Michael A Dekker; Erin S Valenti; Fabiola A Arbelo Cruz; Ady M Correa; Justin L Poklis; Alphonse Poklis
Journal:  Psychosomatics       Date:  2014-11-06       Impact factor: 2.386

3.  Neurochemical pharmacology of psychoactive substituted N-benzylphenethylamines: High potency agonists at 5-HT2A receptors.

Authors:  Amy J Eshleman; Katherine M Wolfrum; John F Reed; Sunyoung O Kim; Robert A Johnson; Aaron Janowsky
Journal:  Biochem Pharmacol       Date:  2018-09-25       Impact factor: 5.858

4.  Chronic treatment with a metabotropic mGlu2/3 receptor agonist diminishes behavioral response to a phenethylamine hallucinogen.

Authors:  Adam L Halberstadt; Jochem V F van der Zee; Muhammad Chatha; Mark A Geyer; Susan B Powell
Journal:  Psychopharmacology (Berl)       Date:  2018-11-17       Impact factor: 4.530

5.  Synthesis and structure-activity relationships of N-benzyl phenethylamines as 5-HT2A/2C agonists.

Authors:  Martin Hansen; Karina Phonekeo; James S Paine; Sebastian Leth-Petersen; Mikael Begtrup; Hans Bräuner-Osborne; Jesper L Kristensen
Journal:  ACS Chem Neurosci       Date:  2014-01-15       Impact factor: 4.418

6.  Receptor binding profiles and behavioral pharmacology of ring-substituted N,N-diallyltryptamine analogs.

Authors:  Landon M Klein; Nicholas V Cozzi; Paul F Daley; Simon D Brandt; Adam L Halberstadt
Journal:  Neuropharmacology       Date:  2018-02-27       Impact factor: 5.250

7.  Serotonergic Psychedelics: Experimental Approaches for Assessing Mechanisms of Action.

Authors:  Clinton E Canal
Journal:  Handb Exp Pharmacol       Date:  2018

8.  Comparative neuropharmacology of N-(2-methoxybenzyl)-2,5-dimethoxyphenethylamine (NBOMe) hallucinogens and their 2C counterparts in male rats.

Authors:  Joshua S Elmore; Ann M Decker; Agnieszka Sulima; Kenner C Rice; John S Partilla; Bruce E Blough; Michael H Baumann
Journal:  Neuropharmacology       Date:  2018-03-01       Impact factor: 5.250

9.  Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775).

Authors:  Simon D Brandt; Pierce V Kavanagh; Brendan Twamley; Folker Westphal; Simon P Elliott; Jason Wallach; Alexander Stratford; Landon M Klein; John D McCorvy; David E Nichols; Adam L Halberstadt
Journal:  Drug Test Anal       Date:  2017-07-27       Impact factor: 3.345

Review 10.  Recent advances in the neuropsychopharmacology of serotonergic hallucinogens.

Authors:  Adam L Halberstadt
Journal:  Behav Brain Res       Date:  2014-07-15       Impact factor: 3.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.